Novo Nordisk news

Novo Nordisk A/S - Share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

EFSD/Novo Nordisk partnership for diabetes research in Europe

Three million euros to support European diabetes research

Novo Nordisk A/S - Share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Novo Nordisk A/S - Share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

New study results show that patients have higher treatment satisfaction with liraglutide compared to exenatide

Montreal, Canada – New data on patient treatment satisfaction from the LEAD™ 6 trial presented today at the 20th World Diabetes Congress (International Diabetes Federation) shows that patients have higher overall treatment satisfaction with liraglutide than they do with exenatide.

Syndicate content